Corrigendum: Treatment-resistant and Multi-therapy resistant criteria for bipolar depression: A consensus definition (The British Journal of Psychiatry (2019) 214 (27-35) DOI: 10.1192/bjp.2018.257);Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: Consensus definition

British Journal of Psychiatry

Volumn 214, Issue 1, 2019, Pages 27-35

  Hidalgo Mazzei, Diego ^a,b   Berk, Michael ^c,d,e,f,g   Cipriani, Andrea ^h,i   Cleare, Anthony J ^a,j   Florio, Arianna Di ^k   Dietch, Daniel ^a   Geddes, John R ⁱ   Goodwin, Guy M ^l   Grunze, Heinz ^m   Hayes, Joseph F ^n,o   Jones, Ian ^k   Kasper, Siegfried ^p   Macritchie, Karine ^j   McAllister Williams, R Hamish ^q,r   Morriss, Richard ^s   Nayrouz, Sam ^t   Pappa, Sofia ^t   Soares, Jair C ^u   Smith, Daniel J ^v,w   Suppes, Trisha ^x,y   Talbot, Peter ^z   Vieta, Eduard ^r,aa   Watson, Stuart ^ab,ac   Yatham, Lakshmi N ^ac   Young, Allan H ^j,ad   Stokes, Paul R A ^j,ae   more..

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c BARWON HEALTH   (Australia)

^d IMPACT Strategic Research Centre   (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f Orygen The National Centre of Excellence in Youth Mental Health   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^j SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^k CARDIFF UNIVERSITY   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m Klinikum am Weissenhof   (Germany)

ⁿ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^o CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

^p MEDICAL UNIVERSITY OF VIENNA   (Austria)

^q NEWCASTLE UNIVERSITY   (United Kingdom)

^r TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^s NOTTINGHAMSHIRE HEALTHCARE NHS TRUST   (United Kingdom)

^t WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^u UNIVERSITY OF GLASGOW   (United Kingdom)

^v UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^w University of Texas Harris County Psychiatric Center   (United States)

^x STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y VA Palo Alto Bipolar and Depression Research Program   (United States)

^z UNIVERSITY OF MANCHESTER   (United Kingdom)

^aa UNIVERSITY OF BARCELONA   (Spain)

^ab UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^ac VANCOUVER COASTAL HEALTH   (Canada)

^ad Psychological Medicine and Integrated Care Clinical Academic Group   (United Kingdom)

^ae National Affective Disorders Service   (United Kingdom)

more..

Author keywords

bipolar disorder; consensus; definition; depression; Treatment resistant; corrigendum

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; LAMOTRIGINE; LITHIUM; LURASIDONE; OLANZAPINE; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COGNITIVE BEHAVIORAL THERAPY; CONSENSUS; DELPHI STUDY; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; MULTI THERAPY RESISTANT DEPRESSION; PRACTICE GUIDELINE; REMISSION; STANDARD; TREATMENT RESISTANT DEPRESSION; BIPOLAR DISORDER; DEPRESSION;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CONSENSUS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS;

EID: 85058883342     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.2019.36     Document Type: Erratum

References (45)

1. Kupka RW, Altshuler LL, Nolen WA, Suppes T, Luckenbaugh DA, Leverich GS, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007; 9: 531-5.
2. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005; 66 (suppl 5): 5-10.
3. Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep 2014; 16: 431.
4. Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen T-J, Cheng J-Y, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 2012; 200: 45-51.
5. Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. Bipolar Disord 2013; 15: 61-9.
6. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156: 1164-9.
7. Pacchiarotti I, Mazzarini L, Colom F, Sanchez-Moreno J, Girardi P, Kotzalidis GD, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-40.
8. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-36.
9. Poon SH, Sim K. Evidence-based pharmacological approaches for treatmentresistant bipolar disorder. Treat mood Disord 2015: 83-93.
10. McAllister-Williams RH, Christmas DMB, Cleare AJ, Currie A, Gledhill J, Insole L, et al. Multiple-therapy-resistant major depressive disorder: a clinically important concept. Br J Psychiatry 2018 212, 274-278.
11. Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes TRH, Cipriani A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30: 495-553.
12. The National Institute for Health and Care Excellence. Bipolar Disorder: Assessment and Management. NICE Clinical Guideline 185. NICE, 2014.
13. Dalkey NC. The Delphi Method: An Experimental Study of Group Opinion. RAND Corporation, 1969.
14. Jorm AF. Using the Delphi expert consensus method in mental health research. Aust New Zeal J Psychiatry 2015; 49: 887-97.
15. Donaldson L. Expert patients usher in a new era of opportunity for the NHS. BMJ 2003; 326: 1279-80.
16. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170: 1249-62.
17. Medicines and Healthcare Products Regulatory Agency. Valproate Medicines (Epilim , Depakote ): Contraindicated in Women and Girls of Childbearing Potential Unless Conditions of Pregnancy Prevention Programme are Met. Medicines and Healthcare Products Regulatory Agency, 2018 (https://www. gov.uk/drug-safety-update/valproate-medicines-epilim-depakote-contraindicated-in-women-and-girls-of-childbearing-potential-unless-conditions-ofpregnancy-prevention-programme-are-met).
18. Forty L, Smith D, Jones L, Jones I, Caesar S, Cooper C, et al. Clinical differences between bipolar and unipolar depression. Br J Psychiatry 2008; 192: 388-9.
19. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A doubleblind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71: 150-62.
20. Hirschfeld RM, Calabrese JR, Frye MA, Lavori PW, Sachs G, Thase ME, et al. Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening. Psychopharmacol Bull 2007; 40: 7-14.
21. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-33.
22. Yatham LN, Kennedy SH, Parikh S V, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170.
23. Samalin L, Vieta E, Okasha TA, Uddin MJ, Ahmadi Abhari SA, Nacef F, et al. Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions. Sci Rep 2016; 6: 25920.
24. Tondo L, Baldessarini RJ, Vázquez G, Lepri B, Visioli C. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand 2013; 127: 355-64.
25. McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016; 3: 1138-46.
26. Jauhar S, McKenna PJ, Laws KR. NICE guidance on psychological treatments for bipolar disorder: searching for the evidence. Lancet Psychiatry 2016; 3: 386-8.
27. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/ metabolic system and treatment outcome. Bipolar Disord 2010; 12: 404-13.
28. Lee JH, Dunner DL. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. Depress Anxiety 2008; 25: 91-7.
29. Deckersbach T, Peters AT, Sylvia L, Urdahl A, Magalhães PVS, Otto MW, et al. Do comorbid anxiety disorders moderate the effects of psychotherapy for bipolar disorder? Results from STEP-BD. Am J Psychiatry 2014; 171: 178-86.
30. Swartz HA, Pilkonis PA, Frank E, Proietti JM, Scott J. Acute treatment outcomes in patientswith bipolar I disorder and co-morbid borderline personality disorder receiving medication and psychotherapy. Bipolar Disord 2005; 7: 192-7.
31. Zimmerman M. A Review of 20 years of research on overdiagnosis and underdiagnosis in the rhode Island methods to improve diagnostic assessment and services (MIDAS) project. Can J Psychiatry 2016; 61: 71-9.
32. Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord 2013; 144: 191-8.
33. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-42.
34. Cooper SJ, Reynolds GP, Barnes T, England E, Haddad P, Heald A, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2016; 30: 717-48.
35. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014; 348: g1151.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (5th edn) (DSM-5). APA, 2013.
37. McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. The prevalence and illness characteristics of DSM-5-defined 'mixed feature specifier' in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord 2015; 172: 259-64.
38. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin J-M, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 2018; 19: 2-58.
39. Verdolini N, Hidalgo-Mazzei D, Murru A, Pacchiarotti I, Samalin L, Young AH, et al. Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines. Acta Psychiatr Scand 2018; 138: 196-222.
40. Goldberg JF, Allen MH, Miklowitz DA, Bowden CL, Endick CJ, Chessick CA, et al. suicidal ideation and pharmacotherapy among STEP-BD patients. Psychiatr Serv 2005; 56: 1534-40.
41. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 2018; 175: 150-8.
42. Sharma V, Sharma S. Peripartum management of bipolar disorder: what do the latest guidelines recommend? Expert Rev Neurother 2017; 17: 335-44.
43. Graham RK, Tavella G, Parker GB. Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period? J Affect Disord 2018; 228: 216-21.
44. National Institute for Health and Care Excellence (NICE). Antenatal and Postnatal Mental Health. NICE, 2016 (https://www.nice.org.uk/guidance/ qs115).
45. National Institute for Health and Care Excellence. Falls in Older People: Assessing Risk and Prevention. NICE, 2013.